Edotreotide
Gastrin-Producing Neuroendocrine Tumor
Explore 2 assets in Gastrin-Producing Neuroendocrine Tumor →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
British Columbia Cancer Agency
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04915144CT.gov 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastrin-Producing Neuroendocrine Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Edotreotide (this asset) | British Columbia Cancer Agency | P2 | CCC · 52 |
| Everolimus | Emory University | P2 | B |
| Gefitinib | National Cancer Institute (NCI) | P2 | B |
| Capecitabine | ECOG-ACRIN Cancer Research Group | P2 | B |
| Pazopanib | National Cancer Institute (NCI) | P2 | B |
| Omeprazole | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P2 | B |
| Pantoprazole | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P2 | B |
| Regorafenib | University of Southern California | P2 | B |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
+8 more in the Gastrin-Producing Neuroendocrine Tumor cohort
Other indications for Edotreotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Digestive System Neuroendocrine Neoplasm | — | P3 | B · 63 |
| Neuroblastoma | — | P2 | B · 60 |
| Carcinoid Tumor | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Edotreotide in Gastrin-Producing Neuroendocrine Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/edotreotide-gastrin-producing-neuroendocrine-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →